UHRF1 PHD inhibitor MLD5 is a specific compound that selectively inhibits the UHRF1-histone interaction (IC50=7.4 uM), targets the PHD finger of UHRF1, specifically disrupting histone H3 arginine 2 interactions with the PHD finger.UHRF1 PHD inhibitor MLD5 inhibited binding between H3K9me3(FAM) and UHRF1 with IC50 of 24-26 uM, displace UHRF1-histone H3 binding in cells.

UHRF1 PHD inhibitor MLD4 is a specific compound that selectively inhibits the UHRF1-histone interaction (IC50=12.4 uM), targets the PHD finger of UHRF1, specifically disrupting histone H3 arginine 2 interactions with the PHD finger.UHRF1 PHD inhibitor MLD4 inhibited binding between H3K9me3(FAM) and UHRF1 with IC50 of 24-26 uM, displace UHRF1-histone H3 binding in cells.

NJH-2-075 is an alkyne-functionalized probe of EN523, retains binding to OTUB1 in vitro.

IMTPPE (SID3712502) is a novel small molecule capable of inhibiting androgen receptor (AR) transcriptional activity (IC50=1 uM) and protein level in C4-2 prostate cancer cells.

m-PEG5-CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Diuron is a phenylurea herbicide that inhibits photosynthesis by preventing the formation of ATP and NADH. Diuron (2,500 ppm, dietary) increases the incidence of urinary bladder urothelial carcinomas in male and female mice by 73 and 27%, respectively.

Cipepofol (HSK3486), a sedative-hypnotic agent, is a gamma-aminobutyric acid (GABA) receptor potentiator.

RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC50s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely.

CCR2 antagonist 3 is a chemokine receptor 2 (CCR2) antagonist.

L-803087 is a potent and selective somatostatin sst4 receptor agonist with a Ki of 0.7 nM, which is > 280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice.

Glutaminase-IN-3 (compound 657) is a potent glutaminase inhibitor extracted from patent WO2014089048A1, compound 657, has an IC50 of 0.24 μM for Glutaminase 1 (GLS1).

Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.

Paltusotine (CRN00808) is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.

A novel selective, orally available fungal CYP51 (lanosterol 14-α-demethylase) inhibitor.

VT-1598 tosylate is an orally active and selective fungal inhibitor targeting CYP51. VT-1598 tosylate shows anti-fungal activity against C. auris.

BDP8900 (BDP-8900) is a highly potent and selective Myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with IC50 of 43 nM (MRCKβ), >100-fold selectivity over related ROCK1 or ROCK2.

BDP9066 (BDP-9066) is a highly potent and selective Myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with IC50 of 43 nM, >100-fold selectivity over related ROCK1 or ROCK2.

Vitamin D3 octanoate is an octanoate ester of vitamin D3. Vitamin D3 is a naturally occuring form of vitamin D. Vitamin D3 induces cell differentiation and prevents proliferation of cancer cells.

Gefitinib impurity 2 is the impurity of Gefitinib. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity.

10-OH-NBP D4 is deuterium labeled 10-OH-NBP. 10-OH-NBP is a Butylphthalide hydroxylated metabolite and can penetrates the blood-brain barrier (BBB). Butylphthalide exerts neuroprotective effects and has potential for cerebral ischemia research.

Glucopiericidin A is a natural piericidin compound obtained from a marine-derived Streptomyces strain. Glucopiericidin A serves as a glucose transporter (GLUT) chemical probe and suppresses glycolysis. Glucopiericidin A inhibits ATP-dependent filopodia protrusion with Piericidin A and has no effect alone. Glucopiericidin A induces cell apoptosis through reducing the reactive oxygen species (ROS) level by increasing PRDX1 and exhibits potent antitumor efficacy in ACHN mice xenografts.

Salmeterol-D3 is the deuterium labeled Salmeterol. Salmeterol is a long-acting beta2-adrenergic receptor agonist that is used for the study of asthma and chronic obstructive pulmonary disease (COPD).

4,5-Dichloroveratrole is a chlorinated product formed by reaction of Veratryl alcohol with chlorine dioxide solution.

3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol. 3,4-Dehydro Cilostazol is used for pharmacokinetic study.

7-Hydroxycoumarinyl arachidonate (7-HCA) is a fluorogenic substrate of cytosolic phospholipase A2 (PLA2). 7-Hydroxycoumarinyl arachidonat e is also a fluorogenic substrate for monoacylglycerol lipase (MAGL). MAGL protein catalyzes the hydrolysis of 7-Hydroxycoumarinyl arachidonat to generate Arachidonic acid (AA) and the highly fluorescent 7-hydroxyl coumarin. Release of 7-HC can be measured using a fluorometer.

6,7-Dimethyl-8-ribityllumazine is a direct biosynthetic precursor of Riboflavin. 6,7-Dimethyl-8-ribityllumazine is a noncovalently bound fluorophore of Lumazine protein (LumP), which is a fluorescent accessory protein.

Sevelamer carbonate is an orally active and non-calcium-based phosphate binding agent and used for the hyperphosphatemia of chronic kidney disease (CKD)research. Sevelamer carbonate effectively lowers serum phosphorus levels hile having minimal effect on serum calcium or serum chloride levels in vivo. Sevelamer carbonate is considered as an improved, buffered form of sevelamer.

NMTCA (NMTPRO) is a sulfur-containing N-nitrosamino acid. NMTCA can be used as an indicator of endogenous nitrosation by gas chromatography-thermalenergyanalysis.

ONO-7475 is a potent, selective, and orally active novel Anexelekto/MER tyrosine kinase inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. ONO-7475 sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. ONO-7475 combines with Osimertinib provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).